QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
NASDAQ:KNSA

Kiniksa Pharmaceuticals Stock Forecast, Price & News

$11.30
-0.32 (-2.75%)
(As of 12/1/2021 04:00 PM ET)
Add
Compare
Today's Range
$11.30
$12.12
50-Day Range
$10.39
$15.15
52-Week Range
$10.30
$24.70
Volume
310,252 shs
Average Volume
436,825 shs
Market Capitalization
$778.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.07
30 days | 90 days | 365 days | Advanced Chart
Receive KNSA News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Kiniksa Pharmaceuticals logo

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KNSA
Fax
N/A
Employees
168
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$4.57 per share

Profitability

Net Income
$-161.38 million
Pretax Margin
-875.56%

Debt

Price-To-Earnings

Miscellaneous

Free Float
31,647,000
Market Cap
$778.43 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/01/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/22/2022

MarketRank

Overall MarketRank

2.18 out of 5 stars

Medical Sector

397th out of 1,392 stocks

Pharmaceutical Preparations Industry

178th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Kiniksa Pharmaceuticals (NASDAQ:KNSA) Frequently Asked Questions

Is Kiniksa Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Kiniksa Pharmaceuticals stock.
View analyst ratings for Kiniksa Pharmaceuticals
or view top-rated stocks.

How has Kiniksa Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Kiniksa Pharmaceuticals' stock was trading at $16.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KNSA stock has decreased by 29.8% and is now trading at $11.30.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 2,170,000 shares, a decrease of 33.0% from the October 31st total of 3,240,000 shares. Based on an average daily volume of 334,400 shares, the short-interest ratio is presently 6.5 days.
View Kiniksa Pharmaceuticals' Short Interest
.

When is Kiniksa Pharmaceuticals' next earnings date?

Kiniksa Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Kiniksa Pharmaceuticals
.

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) posted its quarterly earnings data on Monday, November, 1st. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.21. The business earned $12.10 million during the quarter, compared to the consensus estimate of $9.92 million.
View Kiniksa Pharmaceuticals' earnings history
.

What price target have analysts set for KNSA?

2 equities research analysts have issued twelve-month price objectives for Kiniksa Pharmaceuticals' stock. Their forecasts range from $24.00 to $34.00. On average, they expect Kiniksa Pharmaceuticals' share price to reach $29.00 in the next twelve months. This suggests a possible upside of 156.6% from the stock's current price.
View analysts' price targets for Kiniksa Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Kiniksa Pharmaceuticals' key executives?

Kiniksa Pharmaceuticals' management team includes the following people:
  • Sanj K. Patel, Chairman & Chief Executive Officer
  • Mark Ragosa, Chief Financial Officer & Senior Vice President
  • John F. Paolini, Chief Medical Officer & Senior Vice President
  • Dana Martin, Senior VP-Global Medical Affairs
  • Ross Moat, Vice President & GM-Rilonacept Franchise

What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?

1 employees have rated Kiniksa Pharmaceuticals CEO Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among Kiniksa Pharmaceuticals' employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

When did Kiniksa Pharmaceuticals IPO?

(KNSA) raised $126 million in an initial public offering on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Kiniksa Pharmaceuticals' stock symbol?

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.55%), Opaleye Management Inc. (1.91%), ArrowMark Colorado Holdings LLC (1.79%), Hudson Bay Capital Management LP (1.68%), Rice Hall James & Associates LLC (1.08%) and Goldman Sachs Group Inc. (0.71%). Company insiders that own Kiniksa Pharmaceuticals stock include John F Paolini, Sanj K Patel and Thomas W Beetham.
View institutional ownership trends for Kiniksa Pharmaceuticals
.

Which major investors are selling Kiniksa Pharmaceuticals stock?

KNSA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Dimensional Fund Advisors LP, Morgan Stanley, Citigroup Inc., Rafferty Asset Management LLC, Citadel Advisors LLC, Los Angeles Capital Management LLC, and New York State Common Retirement Fund. Company insiders that have sold Kiniksa Pharmaceuticals company stock in the last year include Sanj K Patel, and Thomas W Beetham.
View insider buying and selling activity for Kiniksa Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Kiniksa Pharmaceuticals stock?

KNSA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Great Point Partners LLC, Granahan Investment Management Inc. MA, Point72 Asset Management L.P., ArrowMark Colorado Holdings LLC, Hudson Bay Capital Management LP, Opaleye Management Inc., and Rubric Capital Management LP.
View insider buying and selling activity for Kiniksa Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kiniksa Pharmaceuticals' stock price today?

One share of KNSA stock can currently be purchased for approximately $11.30.

How much money does Kiniksa Pharmaceuticals make?

Kiniksa Pharmaceuticals has a market capitalization of $778.43 million. The company earns $-161.38 million in net income (profit) each year or ($2.56) on an earnings per share basis.

How many employees does Kiniksa Pharmaceuticals have?

Kiniksa Pharmaceuticals employs 168 workers across the globe.

What is Kiniksa Pharmaceuticals' official website?

The official website for Kiniksa Pharmaceuticals is www.kiniksa.com.

Where are Kiniksa Pharmaceuticals' headquarters?

Kiniksa Pharmaceuticals is headquartered at CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11.

How can I contact Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 448081896257 or via email at [email protected].


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.